Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Sandrock AlfredPresident and CEO | Voyager TherapeuticsVYGR | Open-market sale10b5-1 plan | 04/02 | 04/03 | 11,511 sh | $3.87 | $44,547.57 | −2.4% |
Sandrock AlfredPresident and CEO | Voyager TherapeuticsVYGR | Open-market sale10b5-1 plan | 02/24 | 02/26 | 14,197 sh | $3.79 | $53,806.63 | −2.8% |
Voyager TherapeuticsVYGR | Open-market sale10b5-1 plan | 02/24 | 02/26 | 4,668 sh | $3.77 | $17,598.36 | −3.0% | |
Swartz RobinCOO & Cbo | Voyager TherapeuticsVYGR | Open-market sale10b5-1 plan | 02/24 | 02/26 | 6,458 sh | $3.77 | $24,346.66 | −3.1% |
Carter Todd AlfredChief Scientific Officer | Voyager TherapeuticsVYGR | Open-market sale10b5-1 plan | 02/24 | 02/26 | 4,174 sh | $3.76 | $15,694.24 | −2.8% |
Sandrock AlfredPresident and CEO | Voyager TherapeuticsVYGR | Open-market sale10b5-1 plan | 02/18 | 02/20 | 11,732 sh | $3.41 | $40,006.12 | −2.3% |
Swartz RobinCOO & Cbo | Voyager TherapeuticsVYGR | Open-market sale10b5-1 plan | 02/18 | 02/20 | 3,882 sh | $3.44 | $13,354.08 | −1.8% |
Carter Todd AlfredChief Scientific Officer | Voyager TherapeuticsVYGR | Open-market sale10b5-1 plan | 02/18 | 02/20 | 3,301 sh | $3.44 | $11,355.44 | −2.2% |
Sandrock AlfredPresident and CEO | Voyager TherapeuticsVYGR | Open-market sale | 02/10 | 02/11 | 12,192 sh | $3.78 | $46,085.76 | −2.3% |
Swartz RobinCOO & Cbo | Voyager TherapeuticsVYGR | Open-market sale | 02/10 | 02/11 | 4,569 sh | $3.85 | $17,590.65 | −2.1% |
Carter Todd AlfredChief Scientific Officer | Voyager TherapeuticsVYGR | Open-market sale | 02/10 | 02/11 | 3,525 sh | $3.85 | $13,571.25 | −2.2% |
Voyager TherapeuticsVYGR | Open-market sale10b5-1 plan | 25/10/03 | 25/10/07 | 7,666 sh | $4.78 | $36,643.48 | −5.8% | |
Toby FergusonChief Medical Officer | Voyager TherapeuticsVYGR | Open-market sale | 25/08/18 | 25/08/20 | 19,000 sh | $3.73 | $70,870 | −12.0% |
Sandrock AlfredPresident and CEO | Voyager TherapeuticsVYGR | Open-market sale | 25/04/02 | 25/04/04 | 10,885 sh | $3.43 | $37,335.55 | −2.5% |
Toby FergusonChief Medical Officer | Voyager TherapeuticsVYGR | Open-market sale | 25/04/02 | 25/04/04 | 10,086 sh | $3.43 | $34,594.98 | −6.0% |
Sandrock AlfredPresident and CEO | Voyager TherapeuticsVYGR | Open-market sale | 25/02/20 | 25/02/24 | 11,702 sh | $4.24 | $49,616.48 | −3.8% |
Swartz RobinCOO & Cbo | Voyager TherapeuticsVYGR | Open-market sale | 25/02/20 | 25/02/24 | 3,894 sh | $4.25 | $16,549.5 | −3.8% |
Carter Todd AlfredChief Scientific Officer | Voyager TherapeuticsVYGR | Open-market sale | 25/02/20 | 25/02/24 | 3,305 sh | $4.26 | $14,079.3 | −4.1% |
Sandrock AlfredPresident & CEO | Voyager TherapeuticsVYGR | Open-market sale | 25/02/11 | 25/02/12 | 16,644 sh | $4.45 | $74,065.8 | −5.1% |
Swartz RobinCOO & Cbo | Voyager TherapeuticsVYGR | Open-market sale | 25/02/11 | 25/02/12 | 6,950 sh | $4.45 | $30,927.5 | −6.4% |